Patient safety and minimizing risk with insulin administration - Role of insulin degludec

Drug, Healthcare and Patient Safety

Volumn 6, Issue 1, 2014, Pages 55-67

  Aye, Myint M ^a   Atkin, Stephen L ^b  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Basal insulin; Diabetes; Hypoglycemia; Safety

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SAFETY; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPODYSTROPHY; MORNING DOSAGE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PATIENT SELECTION; PERIPHERAL EDEMA; PHARMACODYNAMICS; REVIEW;

EID: 84899764881     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S59566     Document Type: Review

References (71)

1. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012; 29(8): 2104-2114.
2. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes 2011; 60 Suppl 1A: 42-LB (abstract).
3. Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007; 23(6): 441-454.
4. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007; 9(5): 648-659.
5. Ding L, Gysemans C, Mathieu C. β-Cell differentiation and regeneration in type 1 diabetes. Diabetes Obes Metab. 2013; 15 Suppl 3: 98-104.
6. Fineberg SK. Application of newer concepts in diabetes. J Am Geriatr Soc. 1966; 14(5): 463-471.
7. National Diabetes Information Clearinghouse (NDIC). Diabetes overview [web page on the Internet]. NIH Publication No 09-3873. Bethesda, MD: NDIC; 2008. Available from: http://diabetes. niddk. nih. gov/dm/pubs/overview/. Accessed January 26, 2014.
8. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36 Suppl 1: S11-S66.
9. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988; 318(19): 1231-1239.
10. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6): 1364-1379.
11. Garber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes Obes Metab. 2009; 11 Suppl 5: 1-5.
12. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6): 1614-1620.
13. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011; 13 Suppl 1: S103-S108.
14. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5): 682-689.
15. Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest. 1976; 58(1): 7-15.
16. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003; 26(6): 1902-1912.
17. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002; 45(7): 937-948.
18. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002; 51(3): 724-733.
19. Graveling AJ, Frier BM. Hypoglycaemia: an overview. Prim Care Diabetes. 2009; 3(3): 131-139.
20. Frier BM, Fisher M. Impaired hypoglycaemia awareness. In: Frier BM, Fisher M, editors. Hypoglycaemia in Clinical Diabetes. Chichester: Wiley; 1999: 111-146.
21. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347: f4533.
22. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes. 2006; 24(3): 115-121.
23. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28(5): 1245-1249.
24. Donnelly LA, Morris AD, Frier BM, et al; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005; 22(6): 749-755.
25. Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Saurio L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005; 29(3): 186-192.
26. Tahrani A, Barnett A, Brod M, Rana M, Peyrot M. GAPP2™: Global survey finds three quarters of patients experience hypoglycaemia on insulin analogue causing dose irregularities and increased blood glucose monitoring. Diabetologia. 2012; 55 Suppl 1: S98-S99.
27. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011; 17(10): 673-680.
28. American Diabetes Association. Insulin administration. Diabetes Care. 2004; 27(90001): 106S-107S.
29. Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012; 8(7): 425-433.
30. Bot M, Pouwer F, de Jonge P, Tack CJ, Geelhoed-Duijvestijn PH, Snoek FJ. Differential associations between depressive symptoms and glycaemic control in outpatients with diabetes. Diabet Med. 2013; 30(3): e115-e122.
31. Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012; 142 Suppl: S8-S21.
32. Katon WJ, Young BA, Russo J, et al. Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Fam Med. 2013; 11(3): 245-250.
33. Yaffe K, Falvey CM, Hamilton N, et al; Health ABC Study. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013; 173(14): 1300-1306.
34. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010; 95(5): 2240-2247.
35. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008; 25(3): 245-254.
36. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005; 48(10): 1988-1995.
37. Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. Epub October 4, 2013.
38. Garber AJ, King AB, Del Prato S, et al; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1498-1507.
39. Heller S, Buse J, Fisher M, et al; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1489-1497.
40. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013; 15(2): 175-184.
41. Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12): 2464-2471.
42. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012; 14(10): 944-950.
43. Heise T, Hövelmann U, Nosek L, Bøttcher S, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011; 60 Suppl 1A: 37-LB (abstract).
44. Heise T, Nosek L, Coester HV, et al. Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. Diabetes 2012; 61 Suppl 1: A259 (abstract).
45. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14(9): 859-864.
46. Kupčová V, Arold G, Roepstorff C, Højbjerre M, Klim S, Haahr HL. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014; 34(2): 127-133.
47. Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2013; 53(2): 175-183.
48. Korsatko S, Deller S, Mader JK, et al. Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus. Drugs Aging. 2013; 31(1): 47-53.
49. Danne T, Bieter T, Blaesig S, et al. Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration. Diabetologia. 2011; 54(Suppl 1): S425.
50. Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352(2): 174-183.
51. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289(17): 2254-2264.
52. Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2013; 20(1): 75-83.
53. Meneghini L, Atkin SL, Gough SC, et al; NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36(4): 858-864.
54. Mathieu C, Hollander P, Miranda-Palma B, et al; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013; 98(3): 1154-1162.
55. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013; 4(6): 605-612.
56. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013; 36(9): 2536-2542.
57. Novo Nordisk. Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2008 [updated September 17, 2013]. Available from: http://clinicaltrials. gov/show/NCT00982644. NLM identifier: NCT00982644. Accessed January 26, 2014.
58. Novo Nordisk. Comparison of NN1250 with insulin glargine plus insulin aspart with/without metformin and with/without pioglitazone in type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 14, 2013]. Available from: http://clinicaltrials. gov/ct2/show/NCT00972283. NLM identifier: NCT00972283. Accessed January 26, 2014.
59. Novo Nordisk. Comparison of NN1250 plus insulin aspart with insulin glargine plus insulin aspart in type 1 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 28, 2013]. Available from: http://clinicaltrials. gov/show/NCT00982228. NLM identifier: NCT00982228. Accessed January 26, 2014.
60. Novo Nordisk. Comparison of NN1250 with insulin glargine in type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 26, 2013]. Available from: http://clinicaltrials. gov/show/NCT01006291. NLM identifier: NCT01006291. Accessed January 26, 2014.
61. Novo Nordisk. Comparison of NN1250 with insulin glargine in type 1 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 20, 2013]. Available from: http://clinicaltrials. gov/show/NCT01079234. NLM identifier: NCT01079234. Accessed January 26, 2014.
62. Novo Nordisk. Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 21, 2013]. Available from: http://clinicaltrials. gov/show/NCT01059799. NLM identifier: NCT01059799. Accessed January 26, 2014.
63. Novo Nordisk. Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 26, 2013]. Available from: http://clinicaltrials. gov/show/NCT01068665. NLM identifier: NCT01068665. Accessed January 26, 2014.
64. Harris SB, Vora J, Christensen T, Kapur R, Brod M. Duration and impact of hypoglycemic events with insulin degludec and insulin glargine-a meta-analysis. Can J Diabetes. 2013; 37(Suppl 4): S54.
65. Tresiba (degludec) [summary of product characteristics]. Bagsværd: Novo Nordisk; 2013. Available from: http://ec. europa. eu/health/documents/community-register/2013/20130121124987/anx_124987_en. pdf. Accessed January 26, 2014.
66. Zinman B, DeVries JH, Bode B, et al; NN1250-3724 (BEGIN: EASY AM), NN1250-3718 (BEGIN: EASY PM) Trial Investigators. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013; 1(2): 123-131.
67. Sharpe L. Improving safety of insulin administration: A pilot audit of hospital staff knowledge. J Diabetes Nurs. 2012; 16(1): 8-16.
68. Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013; 33(7): 515-521.
69. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004; 21(8): 511-530.
70. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157(15): 1681-1686.
71. Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013; 30(12): 1009-1018.